27th Annual Meeting of the European Charcot Foundation, 21 - 23 November 2019, Baveno
Posters presented by Young Investigators (born in 1984 or after):

Basic Studies

Conversion and reversion of JCV antibody serostatus and longitudinal evaluation in a Mexican Multiple Sclerosis population - ID81
CASALLAS VANEGAS Adriana Mexico Efficacy of rituximab at different doses in Neuromyelitis Optica Spectrum Disease (NMOSD). Experience in patients of a tertiary level hospital in Mexico - ID83
View poster - Abstract - Poster presentation recording
Analysis of retinal layers using SS-OCT registries for diagnosing multiple sclerosis - ID54
DROSU Natalia       United States The nucleoside analogues zidovudine, tenofovir alafenamide, and cladribine induce EBV lytic gene expression without subsequent viral replication - ID46
View poster - Abstract
FRAUSSEN Judith          Belgium
Increased frequencies of IgD-CD27- double negative (DN) B cells with a pro-inflammatory phenotype and function in MS patients - ID64
GHAZAEIAN Monireh Iran Post-marketing experience in the safety profile of Interferon beta‐1b biosimilar product in relapsing-remitting multiple sclerosis: 7 years’ follow-up - ID35
View poster - Abstract - Poster presentation recording
HOGLUND Rune Alexander Norway CD4+ T cells in the blood of MS patients respond to predicted epitopes from B cell receptors found in spinal fluid - ID27
View poster - Abstract Winner Young Investigator Award
KLEIN Julia                Germany
Medico-economics of therapy decisions in Multiple Sclerosis: switching to ocrelizumab as compared co extending natalizumab intervals - ID23
MAGHZI Amir-Hadi United States
Microbiome in Multiple Sclerosis: Role of B-cells and Microglia - ID60
MELNIKOV Mikhail Russia
The influence of serotonin on Th17-immune response in multiple sclerosis - ID95
OLIVEIRA Luana Brazil
Imaging features of MOG-IgG related disorders: A comparative study with NMOSD - ID77
POLAK Justyna Poland
The IGHG1 alleles determine the B cell repertoires in the cerebrospinal fluid of patients with multiple sclerosis - ID82
RADOMIR Lihi Israel
Regulating the regulators: the negative fine-tuning of Regulatory B cells by SLAMF5 - ID101
SHARAPKHANOVA Aksholpan Kazakhstan
The predicted value of measuring antibodies against John Cunningham virus in patients with multiple sclerosis - ID22
TELESFORD Kiel United States
Circulating class-switched antibody-secreting cells are enriched among MS patients self-reporting 'Black African', or 'Latin American/Hispanic' ethnicity relative to those reporting 'Caucasian' ethnicity - ID24
TORSETNES Silje Bøen Norway
Assessing immunogenicity of immunoglobulin variable regions - ID100

ANDERSEN Louise Denmark
Dimethyl Fumarate reduces fatigue in patients with relapsing remitting multiple sclerosis - in a prospective 2 year phase IV trial - ID67
ARALBAYEVA Assel Kazakhstan Determining the stage of Parkinson's disease on the scale of Hoehn and Yahr - ID7
View poster - Abstract 
ARALBAYEVA Assel Kazakhstan
Determining cognitive function in Parkinson's disease using a Mini Mental State Examination (MMSE) - ID8
BELETE Daniel    United Kingdom
Variation in cladribine-induced lymphocyte depletion - ID94
GARCIA Christian Alan    Mexico
Anti-AQP4 (+) NMO spectrum disorder associated with central nervous system Tuberculosis - ID85
GOMEZ-FIGUEROA Enrique    Mexico
Pregnancy and Susac Syndrome - ID11
GULDE Philipp Germany
Towards a quantitative MS assessment - ID38
MILLER Catherine    United States
Diroximel Fumarate Demonstrates Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase 3 EVOLVE-MS-2 Study - ID50
PANTAZOU Vasiliki Switzerland
Fingolimod versus dimethyl fumarate in first-ever treatment of multiple sclerosis: the Lausanne real-life experience - ID30
PANTAZOU Vasiliki Switzerland Recurrence of disease activity after fingolimod discontinuation is not rare in older patients previously stable on treatment - ID31
View poster - Abstract Winner Young Investigator Award
SAXENA Gauri    United Kingdom
Development of a novel, anti-drug antibody screening platform to detect neutralising responses following alemtuzumab treatment in relapsing multiple sclerosis - ID59
ZABALA Indhira Mexico Treatment and follow up of patients with NMO AQP4 seropositive diagnosed in the National Institute of Neurology and Neurosurgery Manuel Velasco Suarez - ID87
ZANETTA Chiara Italy 
Long-term follow up of an Italian coohort of pediatric Multiple Sclerosis patients: real world data from San Raffaele Hospital - ID48


BEZZINI Daiana Italy Mortality trends from Multiple Sclerosis in Italy during the period 1980-2015 - ID15
View poster - Abstract - Poster presentation recording
JACOBS Benjamin United Kingdom
Body Mass Index and reduced serum vitamin D levels are independent causal risk factors for Multiple Sclerosis: a Mendelian Randomisation study - ID79
View poster - Abstract Winner Young Investigator Award

White matter myelin alterations are diffuse in Neuromyelitis Optica Spectrum Disorders and prevail on axonal damage - ID51
CHIRIZZI Cristina Italy 
Multicolor 19F-MRI for in vivo Imaging of immune cells activity in a model of multiple sclerosis - ID69
DE MEO Ermelinda Italy 
In-vivo mapping of thalamic pathological mechanisms in pediatric patients with MS - ID53
KALININ Ivan Russia 
Leptomeningeal contrast enhancement is associated with atrophy of subcortical structures in multiple sclerosis: longitudinal study - ID96
KOUBIYR Ismail France 
Dynamic modular-level alterations of structural–functional coupling in clinically isolated syndrome - ID9
View poster - Abstract Winner Young Investigator Award
MARENNA Silvia  Italy
Functional and structural in vivo assessment of demyelination and axonal loss in experimental autoimmune encephalomyelitis mouse model - ID71
MARIANO Romina United Kingdom 
Spinal Cord Atrophy and Diffusion Tensor Imaging in MOGAD, AQP4-Ab NMOSD & MS - ID66
PISA Marco 
OCT measures are associated with disease burden and inflammatory biomarkers in newly diagnosed MS and CIS - ID73
DALLA COSTA Gloria Italy 
Serum neurofilament light levels in patients with PPMS following Ocrelizumab treatment - ID99
View poster - Abstract 
EGGEBRECHT Julius Germany 
Assessing the Long-term Outcomes of Ocrelizumab Treatment in Patients with Multiple Sclerosis in Germany – CONFIDENCE Baseline Characteristics - ID61
FERRE Laura Italy 
Prognostic parameters of medium-term response to fingolimod treatment in Relapsing Remitting Multiple Sclerosis patients - ID90
GOMEZ-FIGERUOA Enrique  Mexico Clinical evolution in mexican patients with seropositive AQP4 Neuromyelitis optica spectrum disorders treated with rituximab - ID80
HAUSSER-KINZEL Silke  Germany  In multiple sclerosis patients, B cells repopulate immature yet more activated upon anti-CD20 antibody therapy - ID28
IAFFALDANO Antonio  Italy  Early selective depletion of Lymphocyte B subsets and Immune Tolerance restoration in Highly Active Relapsing Multiple Sclerosis patients during Cladribine treatment - ID91
NOVI Giovanni  Italy  Tailoring B-cells depleting therapy in MS according to memory B-cells monitoring: a pilot study - ID49
View poster - Abstract Winner Young Investigator Award
PALMERI Serena  Italy  Disease activity after alemtuzumab correlates with specific patterns of immune reconstitution in individuals with multiple sclerosis - ID10
View poster - Abstract 
PREZIOSA Paolo  Italy  Effects of Fingolimod and Natalizumab on slowly expanding lesion occurence over two years of treatment in relapsing-remitting multiple sclerosis - ID58
TORKE Sebastian  Germany Inhibition of Bruton’s Tyrosine Kinase Selectively Prevents Antigen-Activation of B cells and Ameliorates B cell-Mediated Experimental Autoimmune Encephalomyelitis - ID36
ZANETTA Chiara  Italy  Late onset absolute neutropenia following ocrelizumab treatment in Multiple Sclerosis - ID92